STUDY OF OUTCOME OF STATIN THERAPY IN PATIENTS BY CHECKING LIPID PROFILE AFTER 3 MONTHS OF STARTING TREATMENT IN STATIN NAIVE PATIENTS

Shilpa Atwal,Jitender Thakur

doi:10.32553/ijmbs.v6i1.2395

Abstract

Background: To describe the outcome of statin therapy in patients by checking lipid profile after 3 months of starting treatment in statin naive patients Methods: Study was conducted on Patients with indications for statins presenting to cardiology OPD, Medicine OPD and Endocrinology OPD and started on statins at PGIMER, Chandigarh, within a period of 9 months. Results: The mean decrease in total cholesterol, triglycerides, VLDL and LDL levels in primary prevention group mean decrease in after 3 months of statin treatment in comparison to baseline were 17.24%,21.24%, 22.83 % and 33.19% respectively and increase in mean HDL level was 9.55%. The mean decrease in total cholesterol, triglyceride, VLDL and LDL levels in secondary prevention group after 3 months of statin treatment in comparison to baseline were 14.35% 15.80%, 16.17% and 36.92% respectively and increase in mean HDL level was 8.77%. Concluded: So there was statistically significant change in lipid profile from baseline in both primary and secondary prevention groups after 3 months of statin treatment. Keywords: Statin, LDL,VLDL, HDL

Highlights

American College of Cardiology/American Heart Association (ACC/AHA) Guidelines 2013 recommended high dose of statin therapy for patients (≥21 years of age) having any form of CVD or serum low density lipoproteincholesterol (LDL-C) ≥ 190 mg/dL
Background: To describe the outcome of statin therapy in patients by checking lipid profile after 3 months of starting treatment in statin naive patients Methods: Study was conducted on Patients with indications for statins presenting to cardiology OPD, Medicine OPD and Endocrinology OPD and started on statins at PGIMER, Chandigarh, within a period of 9 months
The benefit of statin therapy on the desired clinical outcomes may be lost when patients are poorly compliant to therapy as only 30–40% of patients who are being treated with statins continue medication after one year

Summary

Introduction

American College of Cardiology/American Heart Association (ACC/AHA) Guidelines 2013 recommended high dose of statin therapy for patients (≥21 years of age) having any form of CVD or serum low density lipoproteincholesterol (LDL-C) ≥ 190 mg/dL. The benefit of statin therapy on the desired clinical outcomes may be lost when patients are poorly compliant to therapy as only 30–40% of patients who are being treated with statins continue medication after one year This aspect needs to be explored whether patients despite having less compliance continue to get the benefits of statins in terms of reduction in serum levels of total cholesterol (TC), low density lipoprotein-cholesterol (LDLC). Results: The mean decrease in total cholesterol, triglycerides, VLDL and LDL levels in primary prevention group mean decrease in after 3 months of statin treatment in comparison to baseline were 17.24%,21.24%, 22.83 % and 33.19% respectively and increase in mean HDL level was 9.55%. The mean decrease in total cholesterol, triglyceride, VLDL and LDL levels in secondary prevention group after 3 months of statin treatment in comparison to baseline were 14.35% 15.80%, 16.17% and 36.92% respectively and increase in mean HDL level was 8.77%.

Methods

Results

Conclusion